Trial Profile
A Retrospective Study Assessing Non-Persistence Rates And Related Clinical Outcomes With Dabigatran And Rivaroxaban In Patients With Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2017
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 04 Apr 2017 New trial record
- 12 Mar 2017 Results published in the Heart Journal.